aTyr Pharma Announces Poster Presentations at the American Association for Cancer Research (AACR) Annual Meeting
March 11 2021 - 8:00AM
aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged
in the discovery and development of innovative medicines based on
novel biological pathways, today announced that the company will
present two posters at the upcoming American Association for Cancer
Research (AACR) Annual Meeting, which is being held virtually April
10 – 15 and May 17 – 21.
Details of the poster presentations are as
follows:
Title: The Neuropilin-2 targeting antibody
ATYR2810 inhibits non-small cell lung cancer tumor growth in
monotherapy and combination therapyAuthors: Alison
G. Barber, Zhiwen Xu, Justin Rahman, Hira Lal Goel, Arthur M.
Mercurio, Christoph Burkart, Leslie A. Nangle. aTyr Pharma, San
Diego, CA, UMass Medical School, Boston, MA.Abstract
Number: 5247Session Category: Tumor
BiologySession Title: Human-in-Mouse Models of
Human CancerPoster Number: LB234Permanent
Abstract Number: LB234Date and Time:
April 10 – 15 and May 17 – 21 (9:00AM – 6:00PM ET)
Title: A domain-specific antibody to NRP2
down-regulated epithelial-mesenchymal transition genes and enhanced
efficacy of standard-of-care therapeutics for aggressive breast
cancerAuthors: Zhiwen Xu, Christoph Burkart, Hira
Lal Goel, Justin Rahman, Clara Polizzi, Matt Seikkula, Luke Burman,
Arthur M. Mercurio, Leslie A. Nangle. aTyr Pharma, San Diego, CA,
UMass Medical School, Boston, MA.Abstract Number:
5316Session Category: Experimental and Molecular
Therapeutics Session Title: Biological Therapeutic
AgentsPoster Number: LB095Permanent
Abstract Number: LB095Date and Time:
April 10 – 15 and May 17 – 21 (9:00AM – 6:00PM ET)
About NRP2
Neuropilin-2 (NRP2) is a cell surface receptor
that plays a key role in lymphatic development and in regulating
inflammatory responses. In many forms of cancer, high NRP2
expression is associated with worse outcomes. NRP2 can interact
with multiple ligands and co-receptors through distinct domains to
influence their functional roles, making it a potential drug target
with multiple distinct therapeutic applications. NRP2 interacts
with type 3 semaphorins and plexins to impact inflammation and with
forms of vascular endothelial growth factor (VEGF) and their
receptors, to impact lymphangiogenesis. In addition, NRP2 modulates
interactions between CCL21 and CCR7 potentially impacting homing of
dendritic cells to lymphoid organs. aTyr is currently investigating
NRP2 receptor biology, both internally and in collaboration with
key academic thought leaders, as a novel target for new product
candidates for a variety of diseases, including cancer and
inflammation.
About aTyr
aTyr is a biotherapeutics company engaged in the
discovery and development of innovative medicines based on novel
biological pathways. aTyr’s research and development efforts are
concentrated on a newly discovered area of biology, the
extracellular functionality and signaling pathways of tRNA
synthetases. aTyr has built a global intellectual property estate
directed to a potential pipeline of protein compositions derived
from 20 tRNA synthetase genes and their extracellular targets.
aTyr’s primary focus is ATYR1923, a clinical-stage product
candidate which binds to the Neuropilin-2 receptor and is designed
to down-regulate immune engagement in inflammatory lung diseases.
For more information, please visit http://www.atyrpharma.com.
Forward-Looking Statements
This press release contains forward-looking
statements within the meaning of the Private Securities Litigation
Reform Act of 1995. Forward-looking statements are usually
identified by the use of words such as “anticipates,” “believes,”
“estimates,” “expects,” “intends,” “may,” “plans,” “projects,”
“seeks,” “should,” “will,” and variations of such words or similar
expressions. We intend these forward-looking statements to be
covered by such safe harbor provisions for forward-looking
statements and are making this statement for purposes of complying
with those safe harbor provisions. These forward-looking statements
include statements regarding the potential therapeutic benefits and
applications of NRP2 antibodies, including ATYR2810; timelines and
plans with respect to certain development activities; and certain
development goals. These forward-looking statements also reflect
our current views about our plans, intentions, expectations,
strategies and prospects, which are based on the information
currently available to us and on assumptions we have made. Although
we believe that our plans, intentions, expectations, strategies and
prospects, as reflected in or suggested by these forward-looking
statements, are reasonable, we can give no assurance that the
plans, intentions, expectations or strategies will be attained or
achieved. All forward-looking statements are based on estimates and
assumptions by our management that, although we believe to be
reasonable, are inherently uncertain. Furthermore, actual results
may differ materially from those described in these forward-looking
statements and will be affected by a variety of risks and factors
that are beyond our control including, without limitation,
uncertainty regarding the COVID-19 pandemic, risks associated with
the discovery, development and regulation of our product
candidates, the risk that we or our partners may cease or delay
preclinical or clinical development activities for any of our
existing or future product candidates for a variety of reasons
(including difficulties or delays in patient enrollment in planned
clinical trials), the possibility that existing collaborations
could be terminated early, and the risk that we may not be able to
raise the additional funding required for our business and product
development plans, as well as those risks set forth in our most
recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q
and in our other SEC filings. Except as required by law, we assume
no obligation to update publicly any forward-looking statements,
whether as a result of new information, future events or
otherwise.
Contact: |
Ashlee Dunston |
Director, Investor Relations and
Corporate Communications |
adunston@atyrpharma.com |
aTyr Pharma (NASDAQ:LIFE)
Historical Stock Chart
From Mar 2024 to Apr 2024
aTyr Pharma (NASDAQ:LIFE)
Historical Stock Chart
From Apr 2023 to Apr 2024